Target: Asymmetric or symmetric dimethylation at arginine 17 (R17) of histone H3.1 (encoded by HIST1H3A) .
Applications:
HPV E6 Oncoprotein and Gene Transcription
DNA Damage Response
p53 Tumor Suppressor Regulation
Myogenic miRNA Expression
Transcriptional Activation: Asymmetric dimethylation (H3R17me2a) is catalyzed by CARM1/PRMT4 and associated with gene activation .
Chromatin Remodeling: Symmetric dimethylation (H3R17me2s) correlates with transcriptional repression and heterochromatin formation .
Disease Links:
| Vendor | Catalog # | Specificity | Applications | Reactivity |
|---|---|---|---|---|
| Abcam | ab8284 | Asymmetric (R17me2a) | WB, IF, IHC, PepArr | Human, mouse |
| Active Motif | 39709 | Asymmetric (R17me2a) | WB, IF, ChIP | Human, vertebrates |
| Merck Millipore | 07-214 | Symmetric (R17me2s) | WB, ELISA, ICC | Human, mouse |
| Avantor | 77687-960 | Symmetric (R17me2s) | IF, IHC | Human |
Specificity: Validated using peptide inhibition assays (e.g., ab8284 shows no cross-reactivity with mono-methyl or symmetric di-methyl peptides) .
Band Patterns: Detects 15–17 kDa bands (core histone H3) in WB, with additional higher-weight bands in some contexts (e.g., 55–90 kDa in HeLa lysates) .
Positive Controls: HeLa nuclear extract is widely recommended .